$XBI $127 -1%
Covid Updates
$NVAX -2% Novavax Statement on Participation in Mix-and-Match COVID-19 Vaccine Booster Trial in the United Kingdom. source
$AZN -1% AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan. source
Pipeline Updates
$MCRB -2% SERES THERAPEUTICS PRESENTS DATA ACROSS ITS BROAD MICROBIOME PIPELINE INCLUDING NEW 24-WEEK DATA FROM SER-109 PHASE 3 ECOSPOR III STUDY IN RECURRENT C. DIFFICILE INFECTION AT DIGESTIVE DISEASE WEEK 2021. source
$HALO -1% Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®. source
$VIR +1% EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s Sotrovimab For the Early Treatment of COVID-19. source
$ATNX -1% Athenex Announces Klisyri® (tirbanibulin) Receives Positive CHMP Opinion from the European Medicines Agency (EMA) for the Treatment of Actinic Keratosis of the Face or Scalp. source
$RYTM +1% Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency. source
$RYTM +1% Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency. source
$ALBO +5% Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC). source
$MYOV +3% Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids. source
$ANVS +125% ANNOVIS BIO ANNOUNCES POSITIVE PHASE 2 DATA – ANVS401 IMPROVES COGNITION IN ALZHEIMER’S DISEASE - PATIENTS’ COGNITION IMPROVED 3.3 POINTS ON ADAS-COG11. source
$BLUE +2% bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD). source
$ONTX -16% Onconova Therapeutics Announces The Initial Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of ON 123300. source
Finance Updates
$VBIV +0% VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures. source
Posted by DV
Opmerkingen